M. Bologna et al., HPLC DETERMINATION OF SIMVASTATIN AND L-654,969 IN HUMAN PLASMA AFTERORAL-ADMINISTRATION OF SIMVASTATIN TO HYPERCHOLESTEROLEMIC PATIENTS, International journal of immunopathology and pharmacology, 7(1), 1994, pp. 79-85
A sensitive, specific and rapid HPLC procedure was developed in order
to monitor plasma levels of simvastatin (MK-733), a novel and potent c
ompetitive inhibitor of 3-Hydroxymethyl-glutaryl CoA reductase, and it
s biologically active hydroxyacid metabolite, L-654-969. This method w
as applied to a series of plasma samples collected from hypercholester
olemic patients (n=10) at various times after a single 10 mg oral dose
of simvastatin. A peak plasma level of simvastatin was observed at 30
minutes and peak levels of its major metabolite were observed at 60 m
inutes, with disappearance of these chemicals within 8-24 hours after
the administration. Clinical and experimental relevance of this method
for the pharmacokinetic assessment and the organ specificity of the d
rug distribution in the body are discussed.